Joseph Fraumeni's 1969 Family Studies Established TP53 as Core Driver of Multi-Cancer Hereditary Risk

Fraumeni and Li examined 24 kindreds in 1969 and documented a 90-fold excess of childhood cancers plus adult tumors, establishing the first clear hereditary cancer syndrome before any gene was known. Their observational series in Annals of Internal Medicine supplied the clinical phenotype that subsequent linkage studies used to localize TP53 on 17p13.1. The same cohort later yielded the first prospective data showing that annual whole-body MRI plus biochemical screening reduces mortality in mutation carriers by approximately 20 percent over ten years. Molecular epidemiology, the field Fraumeni named, shifted from family aggregation tables to population-scale sequencing. Current estimates indicate 1 in 3,500 to 1 in 5,000 individuals carry pathogenic TP53 variants; most remain undiagnosed until a second cancer appears. Integration of these variants into polygenic risk scores now refines lifetime risk estimates beyond the classic 90 percent figure and informs trials of preventive agents such as metformin. Remaining gaps include penetrance modifiers and optimal imaging intervals for children. Ongoing international registries aim to enroll 5,000 carriers by 2028 to power genotype-phenotype analyses that could halve unnecessary radiation exposure from surveillance.